Striatum Gene Expression Correlates for C1HCOUNT45 measured in BXD RI Females obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The C1HCOUNT45 measures Open Field locomotion 30-45 min post cocaine under the domain Cocaine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Striatum Gene Expression Correlates for NOVEL_ACOUNT_1 measured in BXD RI Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The NOVEL_ACOUNT_1 measures Open Field InovelTOTAL locomotion (activity beam breaks) in the center under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Striatum Gene Expression Correlates for ADRE_RIGHT_WT measured in BXD RI Females & Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The ADRE_RIGHT_WT measures Right adrenal weight under the domain Adrenals. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Striatum Gene Expression Correlates for ADRE_RIGHT_WT measured in BXD RI Females obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The ADRE_RIGHT_WT measures Right adrenal weight under the domain Adrenals. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for COCA_TEST_VEHICLE measured in BXD RI Females & Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The COCA_TEST_VEHICLE measures Cocaine CPP - Time (s) in saline paired compartment a under the domain Cocaine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for NX_VCOUNT_3 measured in BXD RI Females obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The NX_VCOUNT_3 measures Naloxone induced Morphine Withdrawal - TOTAL vertical activity counts in 15 minutes under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
QTL for alcohol preference locus on Chr7 at D7Mit105 (126.73 Mbp , Build 37)
Description:
alcohol preference locus spans 101.73 - 151.73 Mbp (NCBI Build 37) on Chr7. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
alcohol preference locus 14, female specific at D7Mit105 with a LOD score of 1.84 (p < 0.004) spans and preference correlation of 0.591 101.73 - 151.73 Mbp (NCBI Build 37) on Chr7. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for METH responses for home cage activity on Chr7 at D7Mit12 (129.57 Mbp , Build 37)
Description:
METH responses for home cage activity spans 104.57 - 154.57 Mbp (NCBI Build 37) on Chr7. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for METH responses for body temperature on Chr7 at Xmv76 (137.02 Mbp , Build 37)
Description:
METH responses for body temperature spans 112.02 - 162.02 Mbp (NCBI Build 37) on Chr7. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL associated with "alcohol preference locus 12, male specific". This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (135707912)
QTL associated with "alcohol preference locus 14, female specific". This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (135707912)
QTL associated with behavioral response to methamphetamines 6. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (143722527)
QTL associated with cystic fibrosis body weight 3. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (126237672)
QTL associated with cystic fibrosis lung disease 4. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (126237672)
QTL associated with collagen induced arthritis 42. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (139448713)
QTL associated with determination of interleukin 4 commitment 2. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (136360966)
QTL associated with ethanol induced thermoregulation 3. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (125537552)
QTL associated with femoral bone morphometry 3. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (125537552)
Authors:
Drake TA, Hannani K, Kabo JM, Villa V, Krass K, Lusis AJ
QTL associated with hepatic lipase activity in BSB 1. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (137807110)
QTL associated with "murine leukemia virus infection QTL, 1". This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (151795777)
Authors:
Panoutsakopoulou V, Little CS, Sieck TG, Blankenhorn EP, Blank KJ
Add Selected GeneSets to Project(s)
Warning: You are not signed in. Adding these genesets to a project will create a guest account for you.
Guest accounts are temporary, and will be removed within 24 hours of creation. Guest accounts can be registered as full accounts, but you cannot associate a guest account with an existing account.
If you already have an account, you should sign into that account before proceeding.